**Letter to the Editor**

**Comparison of the applicability of Hasford score and European Treatment and Outcome Study score in Indian patients with chronic phase chronic myeloid leukemia on imatinib therapy**

**DOI:** 10.4103/sajc.sajc_57_17

Dear Editor,

The Sokal and Hasford scores were developed in the chemotherapy and interferon era (preimatinib era) and are used as prognostic indicators in patients with chronic myeloid leukemia (CML). At present, CML is largely prognosticated on the basis of Hasford score at the time of presentation and subsequently by response to therapy which is ideally monitored by assessing cytogenetic and molecular response. However, in a resource poor setting, serial monitoring by assessing cytogenetic and molecular response is not feasible. Hence, the dependence on scoring systems do not use cytogenetic and molecular response criteria. European Treatment and Outcome Study (EUTOS) scoring system was developed recently to assess prognosis in CML patients on imatinib. We compared the applicability of Hasford score and EUTOS score in Indian patients with chronic phase CML on imatinib therapy.

We compared the EUTOS and Hasford prognostic scores in predicting 3-, 6-, and 12-month hematologic remission in patients of chronic phase CML (CP-CML) on imatinib. Seventy-five patients of CML-CP were enrolled, of which 52 patients were taken prospectively and 23 retrospectively. The Hasford score and EUTOS score were calculated at admission and compared with hematologic remission at 3 months, 6 months, and 12 months. The Hasford score for all patients was calculated based on age, spleen size, basophils, eosinophils, blast percentage, and platelet count at diagnosis.

**Table 1: Hasford and European Treatment and Outcome Study score in chronic phase chronic myeloid leukemia patients on imatinib (n=75)**

| System   | Classification | At admission (percentage of patients) |
|----------|----------------|--------------------------------------|
| Hasford  | Low (≤780)     | 44                                   |
|          | Intermediate (781-1480) | 49.3                               |
|          | High (>1480)   | 6.6                                  |
| EUTOS    | Low risk (≤87) | 78                                   |
|          | High risk (>87) | 21.3                                |

EUTOS = European Treatment and Outcome Study
The score was determined using the online calculator available for Hasford scoring at http://www.pharmacoepi.de/cmlscore.html. The EUTOS score was calculated as \((7 \times \text{basophils}) + (4 \times \text{spleen size})\) at diagnosis, where the spleen was measured in centimeters below the costal margin and basophils, as a percentage ratio. For Hasford score, three risk groups were defined based on the risk score: low risk (≤780), intermediate risk (780–1480), and high risk (>1480). It was intermediate in the majority (49.3%) of the patients at admission. For EUTOS score, two risk groups were defined based on risk score: low risk (≤87) and high risk (>87) [Table 1]. On comparing at 3 months, Hasford score had greater area under the receiver operating characteristic curve 0.687 than EUTOS score (0.395), indicating that Hasford score better predicted the hematologic remission at 3 months than EUTOS score [Figures 1 and 2]. However, no difference was noted in area under the curves at 6 months.

Currently, the usefulness of EUTOS score is uncertain. None of the Indian studies have highlighted its utility to assess prognosis in CML patients on imatinib.[1] Hasford et al.[2] stated that EUTOS score could predict the probability of achieving complete cytogenetic remission (CCyR) and hence predict PFS (Progression-free survival). Xia et al.[3] and Yamamoto et al.[4] did not validate the effectiveness of EUTOS score. They also correlated EUTOS score to CCyR and PFS. The present study observed that EUTOS score was unable to predict hematologic remission in patients of CP-CML on imatinib.

(Continue on page 138...
In a low-resource setting, EUTOS score offers no additional advantage over Hasford score in predicting hematologic remission in patients of CP-CML on imatinib.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Neha Chopra Narang, Mrinalini Kotru, Meera Sikka, Usha Rusia

Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India

Correspondence to: Dr. Mrinalini Kotru, E-mail: mrinalinikotru@gmail.com

References
1. Usman M, Syed NN, Kakepoto GN, Adil SN, Khurshid M. Chronic phase chronic myeloid leukemia: Response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response. J Assoc Physicians India 2007;55:103-7.
2. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 2011;118:686-92.
3. Xia L, Qian W, Yang M, Li Q, Liu F, Xie Y, et al. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy. Onco Targets Ther 2015;8:2485-92.
4. Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, et al. European treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci 2014;105:105-9.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Narang NC, Kotru M, Sikka M, Rusia U. Comparison of the applicability of Hasford score and European Treatment and Outcome Study score in Indian patients with chronic phase chronic myeloid leukemia on imatinib therapy. South Asian J Cancer 2017;6:117-38.

© 2017 The South Asian Journal of Cancer | Published by Wolters Kluwer - Medknow